Opthea Limited ( (AU:OPT) ) has provided an update.
Opthea Limited has requested a trading halt on its securities pending the announcement of the top line results from its Phase 3 COAST clinical trial, which combines OPT-302 with Aflibercept. This trading halt indicates the potential significance of the trial results, which could impact Opthea’s market position and stakeholder interests, as the outcomes may influence future operations and strategic decisions.
More about Opthea Limited
Opthea Limited operates in the biotechnology industry, focusing on the development of therapies for eye diseases. The company is primarily known for its work on treatments for retinal diseases, with a significant market focus on advancing clinical trials for novel therapies.
YTD Price Performance: 9.09%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $467.6M
For a thorough assessment of OPT stock, go to TipRanks’ Stock Analysis page.